Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options on May 21, 2026, for thirteen new non-executive employees, covering an aggregate of 93,340 shares of common stock.
The options, granted under the 2021 Inducement Plan, have a $3.70 exercise price and vest over three years with time-based milestones.
Iovance Biotherapeutics (NASDAQ: IOVA) announced that Interim CEO, President and General Counsel Fred Vogt, PhD, and Chief Financial Officer Corleen Roche will join a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 1:25 p.m. ET in New York.
A live and archived webcast of the event will be accessible via the Iovance investor relations website.
Iovance (NASDAQ: IOVA) reported 1Q26 total revenue of ~$71M, about +45% YoY, with U.S. Amtagvi revenue of ~$60M and global Proleukin revenue of ~$11M. Gross margin was 41%, absorbing one-time maintenance and expansion costs. Management provided 2Q26 revenue guidance $86M–$88M and FY26 $350M–$370M. Clinical highlights include a 40% confirmed ORR in metastatic serous endometrial cancer (first five evaluable patients). Cash was approximately $319M on March 31, 2026, with operations expected to be funded into 2028.
Iovance (NASDAQ: IOVA) will report Q1 2026 financial results and provide corporate updates on Thursday, May 7, 2026 at 8:30 a.m. ET. The company will host a conference call and live audio webcast; an archived webcast will be available for one year.
Investors can register for the live or archived audio webcast via the provided registration link or access it in the Investors section at IR.Iovance.com.
Iovance (NASDAQ: IOVA) approved inducement stock options on April 16, 2026 covering 135,470 shares granted to twelve new non-executive employees under its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $3.80 (closing price on the Date of Grant) and vests over three years.
Vesting: one-third on the first anniversary of each employee’s start date, then eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options covering 3,400 shares to one new non-executive employee, granted on March 19, 2026 under the Amended and Restated 2021 Inducement Plan.
The options carry an exercise price of $3.87 (closing price on the Date of Grant) and vest over three years: one-third at the first anniversary of employment, then eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) announced senior leadership will present at two upcoming investor conferences in March 2026. Presentations: TD Cowen 46th Annual Healthcare Conference on March 2, 2026 at 9:50 a.m. ET and Barclays 28th Annual Global Healthcare Conference fireside chat on March 11, 2026 at 9:30 a.m. ET.
Live and archived webcasts will be available via the company investor events page at the provided webcast link.
Iovance (NASDAQ: IOVA) reported positive early pilot data for lifileucel in advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), showing a 50% confirmed objective response rate (ORR) among the first six evaluable patients.
Patients were heavily pretreated (mean >2 prior lines) with mean baseline tumor burden of 117 mm. Safety was described as favorable and consistent with prior lifileucel studies. Iovance plans a single-arm registrational trial in second-line UPS and DDLPS in Q2 2026 and will engage the FDA for an accelerated approval path.
Iovance (NASDAQ: IOVA) reported fourth-quarter 2025 product revenue of approximately $87 million (about 30% quarter-over-quarter growth) and full-year 2025 revenue of ~$264 million, achieving guidance of $250M–$300M. Gross margin improved to ~50% and cash of ~$303 million is expected to fund operations into Q3 2027.
Key commercial and clinical updates include continued Amtagvi uptake, global regulatory progress, FDA Fast Track designation for lifileucel in previously treated NSCLC, and pipeline trial advances with registrational plans targeting potential lifileucel launch in H2 2027.
Iovance (NASDAQ: IOVA) approved inducement stock options covering 3,600 shares for two new non-executive employees on February 19, 2026. Each option has an exercise price of $2.85 and vests over three years with time-based quarterly installments.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).